Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 2% on Tuesday even after the telehealth company posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected. The firm raised its full-year revenue outlook. Novo Nordisk A/S (NYSE:NVO) suffered a similar fate a week earlier, with shares dropping about 6% […]

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.

Soleil Boughton retains roughly 339,000 shares and additional derivative securities.

This tax-related withholding was tied to quarterly RSU vesting, not discretionary selling.

Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.

This non-discretionary sale was tied to RSU tax withholding; the insider retains 65,734 direct shares and 428,000 derivative securities, per the filing.

The disposition comes as HIMS stock has declined 38% over the past 12 months.

This non-discretionary tax withholding reduced the CTO of Hims' direct holdings, though he retains roughly 194,000 shares and roughly 2 million derivative securities subject to multi-year vesting.

Stock-based compensation vesting triggered mandatory tax withholding, but Dudum retains about 9.7 million shares worth $272 million.

Hims & Hers Health (NYSE:HIMS) is facing a new consumer class action lawsuit alleging misrepresentation of user privacy and unauthorized sharing of sensitive health data. The lawsuit follows a recent FTC civil enforcement action against the company that raised similar concerns about handling of consumer health information. Plaintiffs claim the company misled users about how their health data would be used and shared, potentially affecting customer trust and future regulatory scrutiny. As...

Andrew Dudum told CNBC the agency wanted "more of a headline than a real agreement" after years of cooperative talks

Speaking in an interview with CNBC on Tuesday, Dudum said an AI coach could remind patients to take their medicine, monitor side effects and even connect with healthcare providers.

Investing.com -- Hims & Hers Chief Executive Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit concerning its data sharing practices in an interview that aired Tuesday on CNBC's "Squawk Box."

Andrew Dudum explained CNBC that the FTC’s lawsuit is just a misunderstanding of what he’s doing... but maybe the regulator might understand him just fine?

CEO Andrew Dudum marked the company’s fifth listing anniversary by ringing the NYSE opening bell and declaring its “next phase of growth.”

Subscriber growth accelerated as revenue surged 38% and international expansion took off.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Hims & Hers Health’s second quarter results were driven by strong subscriber growth and a ramp-up in its branded weight loss offerings, yet the market reacted negatively, with shares declining over 5%. Management pointed to accelerated customer acquisition, particularly from new launches in AI-powered services and expanded product categories. CEO Andrew Dudum stressed that the company’s “investment in AI and technology is delivering a health experience that we believe no other company can replic

Oscar Health CEO Mark Bertolini identified uncovered GLP-1 drugs as a potential use case for Hims on the marketplace.

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. […]

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its non-GAAP loss of $0.09 per share was significantly below analysts’ consensus estimates.

By Amina Niasse NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's

Hims & Hers Health stock has pulled back recently yet is still up a little over 3x in five years, which leaves investors weighing that strong long term gain against a valuation profile that screens as neither clearly cheap nor clearly expensive. The share price has delivered about 341% over five years, so anyone looking at Hims & Hers Health today is assessing a company that has already created substantial returns over a medium term horizon. Growth expectations around its telehealth platform...

Morningstar’s $23 fair value implies a 25% downside, with a 'Very High Uncertainty' rating.

HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.

Hims & Hers Health, Inc. reported second-quarter 2026 sales of US$753.21 million, up from US$544.83 million a year earlier, but moved from net income of US$42.51 million to a net loss of US$86.29 million, while also raising full-year 2026 revenue guidance to between US$3.10 billion and US$3.30 billion and issuing higher third-quarter revenue expectations. Alongside this growth outlook, the company is rolling out an AI-powered, personalized weight loss experience on the Hers app, supported by...

Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss...

Hims & Hers Health raised its 2026 revenue outlook to between $3.1 billion and $3.3 billion from its earlier guidance between $2.8 billion and $3 billion.

Hims & Hers Health (HIMS) reported a mixed Q2, with upside in its US business from branded GLP-1 str

Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Revenue beat expectations and guidance rose, but falling margins cloud the outlook

Strong subscriber growth and international expansion drive record performance, offset by margin pressures and FTC legal challenges.

Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally. Chief Financial Officer Yemi Okupe said dome

Hims called Wegovy pill demand “staggering” and plans new testosterone and peptide treatments.

The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -42.86% and +9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close."

Hims stock fell late Monday after its second-quarter loss came in bigger than expected, upsetting a sales beat.

Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%.

The telehealth platform said it now projects $3.1 billion to $3.3 billion in revenue for the year, up from a previous target for $2.8 billion to $3 billion.

SharkNinja (NYSE:SN) reported second-quarter 2026 results marked by accelerating sales growth, higher adjusted earnings and a raised full-year outlook, as the company cited broad demand across domestic and international markets, product categories and sales channels. Net sales increased 22.2% year

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr

Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices and use of patient data. The company addressed the FTC action by outlining its position on how it handles telehealth consultations and consumer information, aiming to reassure users and investors. The lawsuit raises questions about regulatory risk for telehealth providers and how patient data is collected, stored, and used across the...

CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the lowest sticker price in the ...

Hims & Hers Health (HIMS) just introduced an AI powered care experience for Hers weight loss members, including a connected smart scale and app based coaching, giving investors fresh information on its digital health approach. See our latest analysis for Hims & Hers Health. The AI powered weight loss rollout comes at a time when Hims & Hers Health has experienced sharp swings in sentiment, with the share price up 6.51% on the day and 13.76% over seven days, yet down 12.42% over 30 days and...

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

Claritev Corporation (CTEV) delivered earnings and revenue surprises of +14.88% and +4.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?